I 124 dosimetry completed with thyroid dose to 500 cGy or less and tumor dose of 2500 cGy or more.

I131 therapeutic dose calculated from dosimetry. Dose must be in a range of 25 to 150 mCi.

Patients with Eastern Cooperative Oncology Group (ECOG) Performance Status 0-3 will be eligible.

Use of concurrent systemic therapy (hormonal or cytotoxic) if associated with stable disease for at least three months prior to treatment.

Women with locally advanced breast cancer and simultaneous metastases, even if surgery to eradicate local disease has taken place.

Thyroid stimulating hormone (TSH) must be < 0.4 uIU/mL.

White blood cell count >= 1,500 and platelet count >= 40,000

Women receiving thyroid hormone supplements and methimazole.

Ability to understand and the willingness to sign a written informed consent document.

Premenopausal women must use contraception while receiving this treatment and during follow-up period of 42 days.

Exclusion Criteria:

Stage 0-II breast cancer.

Pregnant or nursing women.

Not able to sign informed consent.

Untreated psychiatric disorder.

Women who have not had I124 PET/CT scan and dosimetry calculations.

Radioiodide uptake in non-target organs or bone marrow does not exceed 25 cGy by pre-treatment dosimetry.

Received chemotherapy less than 4 weeks before.

History of thyroid cancer.

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01360177